NCT07163793 - Pilot Study of Reduced Venetoclax Exposure | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 7, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2028

Conditions

Acute Myeloid Leukemia in Remission

Interventions

DRUG

Azacitidine

Given Day 1-7 with Venetoclax Day 1-14 every 28 days until off study

DRUG

Decitabine

Given Day 1-5 with Venetoclax Day 1-14 every 28 days until off

DRUG

Venetoclax

Venetoclax up to 400mg a day on Day 1-14 every 28 days until off in combination with Azacitidine or Decitabine

Trial Locations (1)

RECRUITING

Zuckerberg Cancer Center, New Hyde Park